NCT04524832View on ClinicalTrials.gov

Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

February 25, 2022

Study Completion Date

February 25, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Oral semaglutide

Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY